Cantor Fitzgerald analyst Eric Schmidt reiterated an Overweight rating on Verastem (NASDAQ: VSTM).

The analyst commented, "Verastem is fast approaching a key readout — initial Phase 1/2 dose expansion data on its KRAS G12D inhibitor VS-7375. The company will be hosting a webinar on October 14 to discuss data on ~20 patients with refractory pancreatic cancer (PDAC), ~20 patients with refractory lung cancer (NSCLC), and ~10 patients with refractory colorectal cancer (CRC)."

For an analyst ratings summary and ratings history on Verastem click here. For more ratings news on Verastem click here.

Shares of Verastem closed at $7.74 yesterday.